EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Atorvastatin Safety Reappraised: From Pharmacogenomic Mechanisms to Personalized Risk Management

Hanyu Wang iD, Yue Pan, Yiming Li iD, Pan Zhai iD

Cardiovascular Therapeutics · 2026

DOI: 10.1155/cdr/4127131 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Therapeutics, 2026. Verfasst von Hanyu Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China, znhospital.cn. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atorvastatin, Pharmacogenetics, Precision Medicine. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhongnan Hospital of Wuhan University, Hubei Provincial Administration of Traditional Chinese Medicine Scientific Research Project - Traditional Chinese Medicine Joint Fund, Hubei Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atorvastatin remains a cornerstone of lipid‐lowering therapy and cardiovascular prevention, but concerns about adverse effects continue to undermine adherence and long‐term clinical benefit. This structured narrative review critically reappraises its safety profile by integrating evidence from randomized trials, meta‐analyses, observational studies, pharmacovigilance analyses, case reports, and preclinical models. Evidence is interpreted according to study design, with controlled and synthesized human data guiding clinical conclusions and lower level evidence treated as supportive or hypothesis‐generating. Overall, atorvastatin provides substantial cardiovascular protection, whereas serious adverse reactions are uncommon. The principal clinical concerns are statin‐associated muscle symptoms, hepatic laboratory abnormalities, drug–drug interactions, and a small dose‐ and susceptibility‐dependent increase in new‐onset diabetes. Safety is shaped by dose, comorbidities, interacting medicines, pharmacokinetic variability, and transporter variants, particularly SLCO1B1, although the clinical actionability of other pharmacogenomic markers remains limited. We, therefore, emphasize individualized risk assessment, interaction review, appropriate monitoring, dechallenge and rechallenge, dose adjustment, alternative statins, and nonstatin combination therapy when needed. Experimental delivery systems and mechanistic findings may inform future strategies but do not yet establish improved clinical safety. Taken together, the evidence supports a benefit‐centered, evidence‐stratified framework that addresses genuine toxicity without overstating uncertain safety signals or unnecessarily discontinuing effective therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsAtorvastatinPharmacogeneticsPrecision MedicinePharmacogenomic VariantsCardiovascular DiseasesDyslipidemiasHumansDrug InteractionsAnimalsRisk AssessmentRisk FactorsTreatment OutcomePharmacovigilanceRisk Management

Stichwörter der Autor:innen

atorvastatindrug–drug interactionshepatotoxicitymyotoxicitypharmacogenomicspharmacokineticspharmacovigilance

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsAtorvastatin

Autor:innen und Institutionen

  • Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China, znhospital.cn.
  • Department of Integrated Traditional Chinese Medicine and Western Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China, znhospital.cn.

ORCID-Profile: Hanyu Wang, Yiming Li, Pan Zhai

Förderung

  • Zhongnan Hospital of Wuhan University
  • Hubei Provincial Administration of Traditional Chinese Medicine Scientific Research Project - Traditional Chinese Medicine Joint Fund
  • Hubei Provincial Natural Science Foundation

Zitieren

APA

Wang, H., Pan, Y., Li, Y., & Zhai, P. (2026). Atorvastatin Safety Reappraised: From Pharmacogenomic Mechanisms to Personalized Risk Management. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/4127131

Vancouver

Wang H, Pan Y, Li Y, Zhai P. Atorvastatin Safety Reappraised: From Pharmacogenomic Mechanisms to Personalized Risk Management. Cardiovascular Therapeutics. 2026. doi:10.1155/cdr/4127131

BibTeX
@article{Wang2026,
  author = {Wang, Hanyu and Pan, Yue and Li, Yiming and Zhai, Pan},
  title = {Atorvastatin Safety Reappraised: From Pharmacogenomic Mechanisms to Personalized Risk Management},
  journal = {Cardiovascular Therapeutics},
  year = {2026},
  doi = {10.1155/cdr/4127131}
}
Kostenlos starten →